(Press-News.org) In early 2025, around 4.9 million British adults — almost one in ten — are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The findings, which are based on a nationally representative household survey of 5,260 British adults, are published in BMC Medicine.
GLP-1 and GLP-1/GIP medications help lower blood sugar, support weight loss, and reduce the risk of heart and kidney complications. The GLP-1 and GLP-1/GIP medications liraglutide, semaglutide, and tirzepatide are licensed for weight loss in the UK but only around 220,000 people will be eligible for treatment with these on the NHS between 2025 and 2028.
Sarah Jackson and colleagues investigated the prevalence of use and interest in GLP-1 and GLP-1/GIP medications among British adults — with an average age of 49 years — using survey data collected between January and March 2025 as part of the Smoking Toolkit Study. The authors found that 2.9% of participants reported using GLP-1 or GLP-1/GIP medications within the previous year to support weight loss. Of those who had not recently used these medications for weight loss, 6.5% were interested in doing so within the next year. Extrapolating from these figures, the authors estimate that around 1.6 million British adults may have used GLP-1 or GLP-1/GIP medications to support weight loss between 2024 and early 2025 and that a further 3.3 million were interested in doing so at the start of 2025. Among those who used a GLP-1 or GLP-1/GIP medication to support weight loss within the previous year, 15% reported using a medication that was not licensed for weight loss in the UK. The authors speculate that this could be due to off-label prescribing or individuals acquiring medications through non-medical routes such as online purchases.
The authors found that GLP-1 or GLP-1/GIP medication use and interest was more prevalent among women, those aged between 45 and 55 years, and those who reported experiencing moderate to severe levels of psychological distress within the previous month. Interest in GLP-1 or GLP-1/GIP medications was also higher among individuals reporting difficulties with their finances, and who were not in work due to long-term illness or disability.
The findings highlight substantial demand for GLP-1 or GLP-1/GIP medications to support weight loss in Britain. The authors recommend regular monitoring of their use, health outcomes, and broader impacts on the British healthcare system, and to ensure that they are provided safely, appropriately, sustainably, and fairly.
END
Health: estimated one in ten British adults used or interested in GLP-1 medications for weight loss
2026-01-08
ELSE PRESS RELEASES FROM THIS DATE:
Exercise to treat depression yields similar results to therapy
2026-01-08
Exercise may reduce symptoms of depression to a similar extent as psychological therapy, according to an updated Cochrane review. When compared with antidepressant medication, exercise also showed a similar effect, but the evidence was of low certainty.
Depression is a leading cause of ill health and disability, affecting over 280 million people worldwide. Exercise is low-cost, widely available, and comes with additional health benefits, making it an attractive option for patients and healthcare providers.
The review, conducted by researchers from the University of Lancashire, examined 73 randomized ...
Whooping cough vaccination for pregnant women strengthens babies’ immune system
2026-01-08
Vaccinating women during pregnancy leads to the transfer of antibodies to their newborns. These antibodies were detected not only in blood, but also in the nasal mucosa, the site where whooping cough bacteria enter the body. This has been shown by international research led by Radboud university medical center. ‘The fact that these antibodies reach the nasal mucosa has not been demonstrated before and highlights how effective this vaccination is’.
Since 2019, pregnant women in the Netherlands have been offered a vaccination against whooping cough (pertussis) for their unborn child, known as the 22-week ...
Dramatic decline in new cases of orphanhood in Uganda driven by HIV treatment and prevention programs
2026-01-08
The scale-up of HIV treatment and prevention programs has led to remarkable declines in orphanhood rates in Rakai, Uganda, according to a new study at Columbia University Mailman School of Public Health. Antiretroviral therapy (ART) availability has been the primary driver of these improvements, underscoring the critical importance of sustained investment in HIV programs. Findings from the study, " Incidence and prevalence of orphanhood in Rakai, Uganda: a population-based cohort study, 1995–2022" are published in The Lancet Global Health.
Using data from the Rakai Community ...
Stopping weight loss drugs linked to weight regain and reversal of heart health markers
2026-01-08
Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, finds a study published by The BMJ today.
It shows that the average rate of weight regain is 0.4kg/month after stopping treatment, with weight and risk markers for diabetes and heart disease predicted to return to pre-treatment levels in less than two years.
It also finds that the rate of weight regain after stopping weight loss drugs is almost 4 times faster than after diet and physical activity ...
Higher intake of food preservatives linked to increased cancer risk
2026-01-08
Higher intake of food preservatives, widely used in industrially processed foods and beverages to extend shelf-life, is associated with a modestly increased risk of cancer, finds a study from France published by The BMJ today.
While further research is needed to better understand these links, the researchers say these new data call for the re-evaluation of regulations governing the use of these additives by the food industry to improve consumer protection.
Preservatives are substances added to packaged foods to extend shelf life. Some experimental studies have shown that certain preservatives ...
Mass General Brigham–developed cholera vaccine completes phase 1 trial
2026-01-08
Clinical trial shows promising results for PanChol, a single-dose oral vaccine aimed at the up to 4 million annual cholera cases worldwide
A team of scientists and physicians at Mass General Brigham has developed a single-dose oral cholera vaccine and tested it in a phase 1 clinical trial, with results published in The Lancet Infectious Diseases.
“The devastating cholera outbreak in Haiti in 2010 triggered my desire to create a new oral live-attenuated cholera vaccine,” said co–senior author Matthew ...
First experimental validation of a “150-year-old chemical common sense” direct visualization of the molecular structural changes in the ultrafast anthracene [4+4] photocycloaddition reaction
2026-01-08
Overview
Anthracene—a hydrocarbon known for its strong luminescence and high photo-reactivity—has long been considered one of the most iconic and widely studied organic molecules. Its [4+4] photocycloaddition reaction, first reported in 1867, has underpinned the development of countless photo-functional materials, including actuators, adhesives, and chromic systems.
Despite being a textbook reaction, the structural changes during this photoreaction occur in an extremely short time window (10⁻⁸–10⁻⁶ s), placing the process beyond direct experimental observation for more than a century. Consequently, controlling and visualizing ...
Lack of support for people on weight loss drugs leaves them vulnerable to nutritional deficiencies, say experts
2026-01-08
People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.
In research published today in Obesity Reviews, the team, led by Dr Marie Spreckley from the University of Cambridge, found a lack of robust evidence surrounding nutritional advice and support and the impact this has on factors such as calorie intake, body composition, protein adequacy, and patient experiences.
Weight ...
Dogs’ dinners can have greater climate impact than owners’
2026-01-08
Dogs fed on premium, meat-rich pet food can have a bigger dietary carbon pawprint than their owners, according to the largest study into dog food’s climate impact.
In particular, wet, raw and meat-rich products are associated with substantially higher greenhouse gas emissions than dry dog food.
Overall, the production of ingredients used in UK dog food is estimated to contribute around one per cent of the country’s total greenhouse gas emissions.
The findings highlight the need for greater transparency and better labelling of dog food ingredients to help consumers make informed choices, as pet ownership continues to rise, experts say.
Scientists ...
Are you ready to swap salmon for sprats and sardines?
2026-01-08
Millions of Britons could be ready to swap imported fish for home‑caught favourites like sardines, sprats and anchovies – according to a new study from the University of East Anglia (UEA).
A new report reveals that more than 40 per cent of consumers are willing to experiment with fish they’ve never tried before.
The study suggests the UK is overlooking a major opportunity to improve national health and bolster local economies by embracing its own rich stocks of small, nutritious fish.
The study was led by researchers at UEA’s Centre for Social and Economic Research ...